Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects

Inclusion Criteria: * Healthy males (Cohorts 1 to 7) or healthy WONCBP (Cohort 8) * 18 to 55 years (Cohorts 1 to 7) or 18 to 60 years (Cohort 8)of age at the time of signing informed consent * Body mass index (BMI) of 18.0 to 30.1 kg/m2 as measured at screening * General good physical health determined by medical and surgical history, physical examination, 12-lead ECG, vital signs and clinical laboratory tests * Normal blood pressure: Systolic blood pressure between ≥90 and ≤140 mmHg, Diastolic blood pressure ≤90 mmHg, measured after 10 min rest in supine position at screening, admission and pre-dose * A resting Heart Rate (HR) between ≥40 and ≤90 bpm measured after 10 min rest in supine position at screening, admission and pre-dose * ECG recording without clinically significant abnormality, including QTcF measure of ≤450 msec (male) or ≤470 msec (female) at screening, admission and pre-dose * Having had no febrile seizures or infectious illness for at least 7 days prior to administration of the Investigational Medicinal Product (IMP) * Must be willing and able to communicate and participate in the whole study * Must provide written informed consent * Must agree to adhere to the contraception requirements and life-style restrictions defined in the protocol Exclusion Criteria: * Subjects who have received any IMP in a clinical research study within the 3 months or 90 days prior to Day 1 * Subjects who are study site employees, or immediate family members of a study site or …